![Sebastien Giguere](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Sebastien Giguere is the founder of Valence Discovery, Inc. He received an undergraduate degree from Université Laval in 2014.
Eerdere bekende functies van Sebastien Giguere
Bedrijven | Functie | Einde |
---|---|---|
Valence Discovery, Inc.
![]() Valence Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Recursion Pharmaceuticals, Inc., Valence Discovery, Inc. is a Canadian company committed to unlocking the true potential of deep learning in drug design. The company is based in Montréal, Canada, and is pioneering the application of few-shot learning in drug design. Valence's AI-enabled drug design platform has been extensively validated and is currently being used to identify and design drug candidates in collaboration with industry-leading partners. The company is developing and deploying novel machine learning methods for molecular property prediction, generative chemistry, and multiparameter optimization. The company was founded by Sebastian Giguere, Prudencio Tossou, Daniel Cohen, Therence Bois, Sebastien Giguere, and Daniel Cohen has been the CEO since incorporation. Valence Discovery was acquired by Recursion Pharmaceuticals, Inc. on May 16, 2023 for $35.35 million. | Algemeen Directeur | - |
Opleiding van Sebastien Giguere
Université Laval | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Valence Discovery, Inc.
![]() Valence Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Recursion Pharmaceuticals, Inc., Valence Discovery, Inc. is a Canadian company committed to unlocking the true potential of deep learning in drug design. The company is based in Montréal, Canada, and is pioneering the application of few-shot learning in drug design. Valence's AI-enabled drug design platform has been extensively validated and is currently being used to identify and design drug candidates in collaboration with industry-leading partners. The company is developing and deploying novel machine learning methods for molecular property prediction, generative chemistry, and multiparameter optimization. The company was founded by Sebastian Giguere, Prudencio Tossou, Daniel Cohen, Therence Bois, Sebastien Giguere, and Daniel Cohen has been the CEO since incorporation. Valence Discovery was acquired by Recursion Pharmaceuticals, Inc. on May 16, 2023 for $35.35 million. | Commercial Services |